维尔生物技术

最新新闻

• 评级变动
  Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $24
  \u5e02\u573a\u8d44\u8baf · 2026/4/16
• BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• 评级变动
  BofA Securities Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/5/14
• 公司公告
  Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
  SEC · 2026/5/29
• 公司公告
  Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
  SEC · 2025/6/3
• 公司公告
  Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.
  SEC · 2025/2/26
• Needham Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $18 to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $15 to $30
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $17
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
  TipRanks · 2026/6/11
• 评级变动
  Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $30
  \u5e02\u573a\u8d44\u8baf · 2026/6/1
• 公司公告
  Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Director Hatfield Jeffrey S.
  SEC · 2024/6/4
• 评级变动
  Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Raises Target Price to $27
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• 评级变动
  A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $16 to $30
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  Leerink Partners Maintains Vir Biotechnology(VIR.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/5/27
• 公司公告
  Vir Biotechnology | 4: Statement of changes in beneficial ownership of securities-Officer HANLY ANN M.
  SEC · 2024/4/3
• H.C. Wainwright Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Buy Rating, Cuts Target Price to $23
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• Insiders Of Vir Biotechnology Make A Tidy Sum Selling At US$8.85
  Simply Wall St · 2026/8/28

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。